PDLI Insider Trading Activity and SEC Form 4 Filings
PDLI insider trading summary
No open-market insider purchases or sales of Pdl Biopharma, Inc. (PDLI) have been reported on SEC Form 4 in the past 12 months.
Latest PDLI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 1, 2021 | Silver Point Capital L.P. | 10% Owner | Buy | $383K (187,061 @ $2.05) |
| Feb 1, 2021 | Edward A Mule | 10% Owner | Buy | $383K (187,061 @ $2.05) |
| Feb 1, 2021 | Robert J O'Shea | 10% Owner | Buy | $383K (187,061 @ $2.05) |
| Dec 30, 2020 | Robert J O'Shea | 10% Owner | Buy | $15.8M (6,325,213 @ $2.50) |
| Dec 30, 2020 | David W Gryska | Director | Sell | $55K (20,000 @ $2.74) |
| Dec 30, 2020 | Silver Point Capital L.P. | 10% Owner | Buy | $15.8M (6,325,213 @ $2.50) |
| Dec 30, 2020 | Edward A Mule | 10% Owner | Buy | $15.8M (6,325,213 @ $2.50) |
| Dec 29, 2020 | Robert J O'Shea | 10% Owner | Buy | $723K (268,600 @ $2.69) |
| Dec 29, 2020 | Edward A Mule | 10% Owner | Buy | $723K (268,600 @ $2.69) |
| Dec 29, 2020 | Silver Point Capital L.P. | 10% Owner | Buy | $723K (268,600 @ $2.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.